Back to Results
First PageMeta Content
Plastic surgery / Medical specialties / Surgical specialties / Overactive bladder / Urology / Pharmaceutical Benefits Scheme / Urinary incontinence / Botulism / Cystoscopy / Medicine / Botulinum toxin / Neurotoxins


Document Date: 2014-11-06 23:49:41

Open Document

File Size: 681,38 KB

Share Result on Facebook

Company

BOTOX / MSAC / Australian Refined Diagnosis Related Group / Allergan Australia Pty Ltd / PBS / /

Currency

USD / /

Event

Product Issues / FDA Phase / Product Recall / /

IndustryTerm

botulinum toxin products / health services / agreed clinical protocols / clinical management / botulinum toxin product / conservative management / health technology assessments / /

MarketIndex

MBS / /

MedicalCondition

refractory migraine / urinary incontinence / adult spina bifida / neurologic disorder / multiple sclerosis / defined neurological illness / urinary tract infections / idiopathic overactive bladder / spinal cord injury / /

MedicalTreatment

clinical protocols / /

Organization

Pharmaceutical Benefits Advisory Committee / Therapeutic Goods Administration / Australian Health Ministers’ Advisory Council / Medical Services Advisory Committee / Medicare / /

Person

BOTULINUM TOXIN / /

Position

anaesthetist / Governor / Minister / Executive / General / /

Product

BOTULINUM TOXIN INJECTIONS / effects necessitating / Intravesical injection / intravesical / management / /

Technology

agreed clinical protocols / /

URL

www.msac.gov.au / /

SocialTag